Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognitive Dysfunction
Evaluation of the Efficacy of Naratriptan for the Treatment and Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction
Sponsor: Cady, Roger, M.D.
Terminated
Terminated October 2009 (in 4th year) due to low enrollment and anticipated drug expiration November 2009.
Other terminated trials from Cady, Roger, M.D.
More terminations from Cady, Roger, M.D.
This PHASE4 trial investigates Post Traumatic Headache and is currently terminated or withdrawn. Cady, Roger, M.D. leads this study, which shows 10 recorded versions since 2006 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE4
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE4
▶ Show 5 earlier versions
-
Jun 2018 — Nov 2020 [monthly]
Terminated PHASE4
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE4
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE4
-
Feb 2017 — Aug 2017 [monthly]
Terminated PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE4
First recorded
Oct 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cady, Roger, M.D.
- Clinvest
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .